AP NEWS

Dicerna to Participate in Upcoming Investor Conferences

November 6, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 6, 2018--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in three investor conferences in November.

Stifel 2018 Healthcare Conference, Tuesday, November 13, 2018 at 11:00 a.m. ET in New York. Dr. Fambrough will present a corporate update and overview of the Company’s most advanced GalXC™ pipeline programs, including DCR-PHXC, an investigational RNAi therapeutic in development for the treatment of all forms of primary hyperoxaluria. A live webcast of the presentation can be accessed on the Investors & Media section on the Dicerna website at www.dicerna.com. An archived replay of the webcast will be available on the Company’s website after the conference. Jefferies 2018 London Healthcare Conference, Wednesday, November 14, 2018 at 4:40 p.m. GMT in London, UK. Dr. Fambrough will present a corporate update and overview of the Company’s most advanced GalXC pipeline programs, including DCR-PHXC, an investigational RNAi therapeutic in development for the treatment of all forms of primary hyperoxaluria. A live webcast of the presentation can be accessed on the Investors & Media section on the Dicerna website at www.dicerna.com. An archived replay of the webcast will be available on the Company’s website after the conference. Evercore ISI HealthCONx, Tuesday, November 27, 2018 at 2:45 p.m. ET in Boston. A live audio webcast of the fireside chat can be accessed on the Investors & Media section on the Dicerna website at www.dicerna.com. An archived replay of the audio webcast will be available on the Company’s website after the conference.

About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative, subcutaneously delivered RNAi-based therapeutics for the treatment of diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases, and viral infectious diseases. Dicerna is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented. Dicerna intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. The Company has strategic collaborations with Boehringer Ingelheim, Eli Lilly and Company, and Alexion Pharmaceuticals. For more information, please visit www.dicerna.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20181106005104/en/

CONTACT: Investors:

Rx Communications Group

Paula Schwartz, 917-322-2216

pschwartz@rxir.com

or

Media:

SmithSolve

Alex Van Rees, 973-442-1555 ext. 111

alex.vanrees@smithsolve.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL OTHER HEALTH RESEARCH OTHER SCIENCE FDA SCIENCE

SOURCE: Dicerna Pharmaceuticals, Inc.

Copyright Business Wire 2018.

PUB: 11/06/2018 07:30 AM/DISC: 11/06/2018 07:30 AM

http://www.businesswire.com/news/home/20181106005104/en

AP RADIO
Update hourly